FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000667931> ?p ?o ?g. }

• W2000667931 endingPage "2653" @default.
• W2000667931 startingPage "2646" @default.
• W2000667931 abstract "Telmisartan is expected to ameliorate not only hypertension, but also metabolic syndrome as a metabosartan. We examined the effects of telmisartan on metabolic syndrome-related molecules such as insulin receptor (IR), peroxisome proliferator-activated receptor gamma (PPAR-γ), and angiotensin 2 type 1 receptor (AT1R) in stroke-resistant spontaneously hypertensive rat (SHR-SR) after transient middle cerebral artery occlusion (tMCAO), by administering telmisartan at either 0 (vehicle), .3 mg/kg/day (low dose), or 3 mg/kg/day (high dose), postoperatively, from 3 months of age and performed immunohistologic analysis at 6, 12, and 18 months of age. Compared with the vehicle group, the 2 telmisartan groups dose dependently decreased the number of IR- and AT1R-positive neurons in the cerebral cortex in the ipsilateral cerebral cortex from 6 to 18 months after tMCAO. On the other hand, the number of PPAR-γ-positive neurons increased in a dose-dependent manner in the 2 telmisartan groups from 6 to 18 months. The present study suggests that telmisartan dose-dependently ameliorated metabolic syndrome-related changes in the poststroke brain of SHR-SR with a direct protective effect (low dose) and an additive benefit, an antihypertensive effect at a high dose, for long-term protection after tMCAO. Telmisartan is expected to ameliorate not only hypertension, but also metabolic syndrome as a metabosartan. We examined the effects of telmisartan on metabolic syndrome-related molecules such as insulin receptor (IR), peroxisome proliferator-activated receptor gamma (PPAR-γ), and angiotensin 2 type 1 receptor (AT1R) in stroke-resistant spontaneously hypertensive rat (SHR-SR) after transient middle cerebral artery occlusion (tMCAO), by administering telmisartan at either 0 (vehicle), .3 mg/kg/day (low dose), or 3 mg/kg/day (high dose), postoperatively, from 3 months of age and performed immunohistologic analysis at 6, 12, and 18 months of age. Compared with the vehicle group, the 2 telmisartan groups dose dependently decreased the number of IR- and AT1R-positive neurons in the cerebral cortex in the ipsilateral cerebral cortex from 6 to 18 months after tMCAO. On the other hand, the number of PPAR-γ-positive neurons increased in a dose-dependent manner in the 2 telmisartan groups from 6 to 18 months. The present study suggests that telmisartan dose-dependently ameliorated metabolic syndrome-related changes in the poststroke brain of SHR-SR with a direct protective effect (low dose) and an additive benefit, an antihypertensive effect at a high dose, for long-term protection after tMCAO." @default.
• W2000667931 created "2016-06-24" @default.
• W2000667931 creator A5007466746 @default.
• W2000667931 creator A5010134994 @default.
• W2000667931 creator A5015988688 @default.
• W2000667931 creator A5020424849 @default.
• W2000667931 creator A5028280894 @default.
• W2000667931 creator A5028770689 @default.
• W2000667931 creator A5035378056 @default.
• W2000667931 creator A5058675749 @default.
• W2000667931 creator A5067675564 @default.
• W2000667931 creator A5072735319 @default.
• W2000667931 creator A5078710220 @default.
• W2000667931 date "2014-11-01" @default.
• W2000667931 modified "2023-10-06" @default.
• W2000667931 title "Long-term Amelioration of Telmisartan on Metabolic Syndrome-related Molecules in Stroke-resistant Spontaneously Hypertensive Rat after Transient Middle Cerebral Artery Occlusion" @default.
• W2000667931 cites W1597210981 @default.
• W2000667931 cites W1972892398 @default.
• W2000667931 cites W1977351047 @default.
• W2000667931 cites W1986968958 @default.
• W2000667931 cites W1988870963 @default.
• W2000667931 cites W1991169415 @default.
• W2000667931 cites W1995753814 @default.
• W2000667931 cites W2000596634 @default.
• W2000667931 cites W2009869050 @default.
• W2000667931 cites W2010290234 @default.
• W2000667931 cites W2015225720 @default.
• W2000667931 cites W2027360957 @default.
• W2000667931 cites W2027637059 @default.
• W2000667931 cites W2030338284 @default.
• W2000667931 cites W2045696691 @default.
• W2000667931 cites W2046278513 @default.
• W2000667931 cites W2048748448 @default.
• W2000667931 cites W2051393086 @default.
• W2000667931 cites W2077500496 @default.
• W2000667931 cites W2082291507 @default.
• W2000667931 cites W2092287823 @default.
• W2000667931 cites W2098684572 @default.
• W2000667931 cites W2118338530 @default.
• W2000667931 cites W2129316761 @default.
• W2000667931 cites W2129697991 @default.
• W2000667931 cites W2135148756 @default.
• W2000667931 cites W2137851506 @default.
• W2000667931 cites W2142624971 @default.
• W2000667931 cites W2146845495 @default.
• W2000667931 cites W2153194422 @default.
• W2000667931 cites W2158894504 @default.
• W2000667931 cites W2168276527 @default.
• W2000667931 cites W2172692903 @default.
• W2000667931 cites W2328112310 @default.
• W2000667931 cites W2328397703 @default.
• W2000667931 cites W2413281350 @default.
• W2000667931 cites W4229737217 @default.
• W2000667931 doi "https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.06.012" @default.
• W2000667931 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25307428" @default.
• W2000667931 hasPublicationYear "2014" @default.
• W2000667931 type Work @default.
• W2000667931 sameAs 2000667931 @default.
• W2000667931 citedByCount "4" @default.
• W2000667931 countsByYear W20006679312015 @default.
• W2000667931 countsByYear W20006679312016 @default.
• W2000667931 countsByYear W20006679312020 @default.
• W2000667931 countsByYear W20006679312021 @default.
• W2000667931 crossrefType "journal-article" @default.
• W2000667931 hasAuthorship W2000667931A5007466746 @default.
• W2000667931 hasAuthorship W2000667931A5010134994 @default.
• W2000667931 hasAuthorship W2000667931A5015988688 @default.
• W2000667931 hasAuthorship W2000667931A5020424849 @default.
• W2000667931 hasAuthorship W2000667931A5028280894 @default.
• W2000667931 hasAuthorship W2000667931A5028770689 @default.
• W2000667931 hasAuthorship W2000667931A5035378056 @default.
• W2000667931 hasAuthorship W2000667931A5058675749 @default.
• W2000667931 hasAuthorship W2000667931A5067675564 @default.
• W2000667931 hasAuthorship W2000667931A5072735319 @default.
• W2000667931 hasAuthorship W2000667931A5078710220 @default.
• W2000667931 hasConcept C112446052 @default.
• W2000667931 hasConcept C126322002 @default.
• W2000667931 hasConcept C127413603 @default.
• W2000667931 hasConcept C134018914 @default.
• W2000667931 hasConcept C170493617 @default.
• W2000667931 hasConcept C2777391703 @default.
• W2000667931 hasConcept C2779306644 @default.
• W2000667931 hasConcept C2779716603 @default.
• W2000667931 hasConcept C2780578515 @default.
• W2000667931 hasConcept C2780645631 @default.
• W2000667931 hasConcept C2908929049 @default.
• W2000667931 hasConcept C555293320 @default.
• W2000667931 hasConcept C71924100 @default.
• W2000667931 hasConcept C78519656 @default.
• W2000667931 hasConcept C84393581 @default.
• W2000667931 hasConcept C98274493 @default.
• W2000667931 hasConceptScore W2000667931C112446052 @default.
• W2000667931 hasConceptScore W2000667931C126322002 @default.
• W2000667931 hasConceptScore W2000667931C127413603 @default.
• W2000667931 hasConceptScore W2000667931C134018914 @default.
• W2000667931 hasConceptScore W2000667931C170493617 @default.
• W2000667931 hasConceptScore W2000667931C2777391703 @default.
• W2000667931 hasConceptScore W2000667931C2779306644 @default.

• next